Research studies
| Study Name | Population | Protocol |
|---|---|---|
| ApcinteX/SerpinPC/AP-0102 PRESent2 | Haemophilia A & B, with and without inhibitors |
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B |
| CSL222_3005 / IX-TEND 3005 | Severe or Moderately Severe Hemophilia B with Detectable Pretreatment |
AAV5 Neutralizing Antibodies Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies |